This is a U.S. news story, published by Yahoo Finance, that relates primarily to Novo Nordisk news.
For more U.S. news, you can click here:
more U.S. newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Medicaid health programs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest state Medicaid programs news, Medicaid programs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Medicare programReuters
•78% Informative
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly .
Half of the states without coverage said they are considering adding them or evaluating their coverage.
The drugs from a class known as GLP-1 agonists were initially developed to treat type 2 diabetes but also promote weight loss by suppressing hunger.
VR Score
90
Informative language
98
Neutral language
40
Article tone
formal
Language
English
Language complexity
44
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links